Artiva Biotherapeutics Announces Agreement with Merck to Evaluate Combinations of NK Cells with Tri-Specific NK-Cell Engagers

rtiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer cell therapies to treat cancer, announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada.